Business Description
Surrozen Inc
NAICS : 541714
SIC : 2833
ISIN : US86889P2083
Share Class Description:
SRZN: Ordinary SharesTotal Employee Number:
44Description
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 16.16 | |||||
Equity-to-Asset | -1.89 | |||||
Debt-to-Equity | -0.03 | |||||
Debt-to-EBITDA | -0.14 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -15.22 | |||||
Beneish M-Score | -1.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -55.8 | |||||
3-Year EBITDA Growth Rate | 32.8 | |||||
3-Year EPS without NRI Growth Rate | 17.5 | |||||
3-Year FCF Growth Rate | 40.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 52.47 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | -44.62 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 19.63 | |||||
9-Day RSI | 29.26 | |||||
14-Day RSI | 36.26 | |||||
3-1 Month Momentum % | 23.83 | |||||
6-1 Month Momentum % | -5.25 | |||||
12-1 Month Momentum % | 125.53 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.14 | |||||
Quick Ratio | 12.14 | |||||
Cash Ratio | 11.32 | |||||
Days Sales Outstanding | 116.01 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -69.5 | |||||
Shareholder Yield % | -16.33 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -385.28 | |||||
Net Margin % | -2885.33 | |||||
EBITDA Margin % | -383.36 | |||||
FCF Margin % | -303.92 | |||||
OCF Margin % | -301.99 | |||||
ROA % | -312.28 | |||||
ROIC % | -481.93 | |||||
3-Year ROIIC % | -102.56 | |||||
ROC (Joel Greenblatt) % | -692.32 | |||||
ROCE % | -45.16 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 22.27 | |||||
EV-to-EBIT | -2.84 | |||||
EV-to-EBITDA | -2.85 | |||||
EV-to-Revenue | 10.93 | |||||
EV-to-Forward-Revenue | 16.37 | |||||
EV-to-FCF | -3.6 | |||||
Earnings Yield (Greenblatt) % | -35.21 | |||||
FCF Yield % | -15.79 |
GF Valueâ„¢
Surrozen Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Surrozen Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 58 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-16 13:50 | In 8 days | ||
| Guidance call for 2026 | 2026-09-10 09:10 | In 2 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 21.95 (+1.39%) | ||
| H.C. Wainwright 6(th) Annual Ophthalmology Virtual Conference | 2026-07-22 13:00 | 22.99 (+3.42%) | ||
| H.C. Wainwright 4(th) Annual BioConnect Investor Conference | 2026-05-19 11:30 | 27.44 (-2.42%) | ||
| General meeting for 2026 | 2026-05-13 10:00 | 30.66 (+4.64%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 32.64 (-0.64%) | ||
| Annual report for 2025 | 2026-03-23 | 25.15 (-6.23%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 | 25.15 (-6.23%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Surrozen Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers